Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

By Essers Brigitte A.B.   Seferina Shanley C.   Tjan-Heijnen Vivianne C.G.   Severens Johan L.   Novák Annoesjka   Pompen Marjolein   Oron Ulrich H.   Joore Manuela A.  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 375-380

Blackwell Publishing

Access to resources Recommend Favorite

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair   Millward Michael J.  

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

By Norum Jan  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1617-1625

Informa Healthcare

Access to resources Recommend Favorite

Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer

By Simoens Steven  

PharmacoEconomics, Vol. 25, Iss. 3, 2007-01 ,pp. : 181-185

Adis International

Access to resources Recommend Favorite

Adjuvant trastuzumab promising but costly for breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 500, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite